HSIC vs. CAH, PDCO, OMI, MCK, COR, GEHC, BIIB, RMD, ICLR, and PHG
Should you be buying Henry Schein stock or one of its competitors? The main competitors of Henry Schein include Cardinal Health (CAH), Patterson Companies (PDCO), Owens & Minor (OMI), McKesson (MCK), Cencora (COR), GE HealthCare Technologies (GEHC), Biogen (BIIB), ResMed (RMD), ICON Public (ICLR), and Koninklijke Philips (PHG). These companies are all part of the "medical" sector.
Henry Schein (NASDAQ:HSIC) and Cardinal Health (NYSE:CAH) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, community ranking, institutional ownership, analyst recommendations, risk, profitability and earnings.
Henry Schein has a net margin of 3.12% compared to Cardinal Health's net margin of 0.25%. Henry Schein's return on equity of 13.51% beat Cardinal Health's return on equity.
Henry Schein currently has a consensus price target of $81.73, suggesting a potential upside of 17.86%. Cardinal Health has a consensus price target of $107.57, suggesting a potential upside of 8.36%. Given Henry Schein's higher possible upside, analysts clearly believe Henry Schein is more favorable than Cardinal Health.
In the previous week, Henry Schein had 5 more articles in the media than Cardinal Health. MarketBeat recorded 15 mentions for Henry Schein and 10 mentions for Cardinal Health. Cardinal Health's average media sentiment score of 0.68 beat Henry Schein's score of 0.45 indicating that Cardinal Health is being referred to more favorably in the news media.
96.6% of Henry Schein shares are owned by institutional investors. Comparatively, 87.2% of Cardinal Health shares are owned by institutional investors. 1.1% of Henry Schein shares are owned by insiders. Comparatively, 0.2% of Cardinal Health shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Henry Schein has a beta of 0.87, meaning that its stock price is 13% less volatile than the S&P 500. Comparatively, Cardinal Health has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500.
Henry Schein has higher earnings, but lower revenue than Cardinal Health. Henry Schein is trading at a lower price-to-earnings ratio than Cardinal Health, indicating that it is currently the more affordable of the two stocks.
Cardinal Health received 530 more outperform votes than Henry Schein when rated by MarketBeat users. Likewise, 71.70% of users gave Cardinal Health an outperform vote while only 51.54% of users gave Henry Schein an outperform vote.
Summary
Henry Schein beats Cardinal Health on 11 of the 18 factors compared between the two stocks.
Get Henry Schein News Delivered to You Automatically
Sign up to receive the latest news and ratings for HSIC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HSIC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Henry Schein Competitors List
Related Companies and Tools
